Biotech
Ginkgo Bioworks
Ginkgo Bioworks raises $350M Series E at $4.9B valuation
$350M
Total Raised
Series E
Latest Round
2008
Founded
600+
Employees
Boston, MA
1 min read
Quick Facts
Valuation
$4.9B
Latest Round Size
$350M
Latest Round Date
September 2020
Ginkgo Bioworks: Series E Funding Round
Ginkgo Bioworks has successfully raised $350M in Series E funding, reaching a valuation of $4.9B.
Company Overview
Synthetic biology and organism engineering
Funding Details
The Series E round was led by Baillie Gifford, with participation from ARK Investment Management.
Company Information
- Headquarters: Boston, MA
- Founded: 2008
- Employees: 600+
- Category: Biotech
Investment
Ginkgo Bioworks plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series E
- ARK Investment Management: Verified investor in Series E
Key Investors
Baillie Gifford
Lead Investor
Verified investor in Series E
ARK Investment Management
Investor
Verified investor in Series E
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M